<DOC>
	<DOCNO>NCT02346175</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , safety tolerability follow single multiple oral dos 5mg 20 mg SHR3824 Type 2 diabetes mellitus patient .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics , Safety Tolerability SHR3824 Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>BMI:2035kg/m2 ; Medically stable base physical examination , medical history , laboratory result , vital sign measurement , 12lead electrocardiogram ( ECG ) screening ; On stable regimen antihyperglycemic therapy least 8 week prior screen fast plasma glucose ( FPG ) concentration lower 13.9 mmol/L baseline ; Stable antihyperglycemic regimen could include single oral agent ( eg , metformin , sulfonylurea , thiazolidinediones ketone , benzoic acid derivative , dipeptidyl peptidase4 inhibitor , Î±glucosidase inhibitor ) glycated hemoglobin ( HbA1c ) 7.0 % 10.0 % . History clinically significant diabetic complication , type 1 diabetes mellitus , repeat severe hypoglycemic episode . Pregnancy breastfeeding ; Significant acute chronic medical illness , include renal impairment , recent surgery ; Donation blood plasma within 4 week prior start study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
</DOC>